Cliquez ici pour connaître notre offre FCPI 2014

The fast pace of innovation in IT offers compelling investment opportunities

Truffle Capital is a pioneer investor in the exciting field of Energy

Biotechnology has radically transformed medicine over the past 25 years


Wittycell

Wittycell, set up in 2005 as a spin-off from the French Institute Jean Godinot, is a biotechnology company developing novel therapeutic and prophylactic vaccine adjuvants in the field of oncology and infectious diseases.

The vaccine market is estimated at over $18 billion, with new technologies and manufacturing processes driving new applications, increasing demand and higher prices. Wittycell’s potential applications encompass more than 90% of the market.

The Company develops novel lipid adjuvant products exclusively licensed from and developed in collaboration with three world renowned academic institutions, the Scripps Research Institute (California), the University of Chicago and the Brigham Young University (Utah).

Truffle Capital is Wittycell’s majority shareholder.

Truffle Venture board member: Dr. Philippe Pouletty